Pharmaceutical News

RSS

Antiestrogen supplements may reduce risk of melanoma in women with breast cancer

Women with breast cancer who take antiestrogen supplements may be decreasing their risk for melanoma, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

5 Jan 2012

First study to elucidate how statins reduce activation of abnormal blood clotting

People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques within their arteries can rupture triggering the formation of a blood clot called an occlusive thrombus that cuts off the blood supply to their heart or brain.

5 Jan 2012

Study reveals factors associated with prevention, control of HIV infection

New vaccine research in monkeys suggests that scientists are homing in on the critical ingredients of a protective HIV vaccine and identifies new HIV vaccine candidates to test in human clinical trials.

5 Jan 2012

NGP receives investment from Abbott to develop NGP 555 for AD

NeuroGenetic Pharmaceuticals, Inc. (NGP), a privately held biopharmaceutical company focused on Alzheimer's disease (AD) therapeutics, has received an investment from Abbott Biotech Ventures.

5 Jan 2012

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.

5 Jan 2012

Actavis commences distribution of Methylphenidate Hydrochloride Extended-Release Capsules

Actavis Group, an international generic pharmaceuticals company, today announced that it recently received approval from the US Food & Drug Administration to market Methylphenidate Hydrochloride Extended-Release Capsules (LA) CII, USP, 20mg, 30mg, and 40mg. Actavis has first-to-file exclusivity on the 20mg, 30mg, and 40mg strengths.

4 Jan 2012

IQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis

Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since the beginning of 2011.

4 Jan 2012

MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients

Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE (glatiramer acetate injection) experienced significantly increased magnetization transfer ratio.

4 Jan 2012

Losartan may help prevent smoking-related COPD

Working with mice, scientists at Johns Hopkins have successfully used a commonly prescribed blood pressure medicine, losartan (Cozaar), to prevent almost all of the lung damage caused from two months of exposure to cigarette smoke. The treatment specifically targeted lung tissue breakdown, airway wall thickening, inflammation and lung over-expansion.

4 Jan 2012

J&J will not join Medicines Patent Pool; Company's pharma head says mechanism could 'cause disaster'

Pharmaceutical company "Johnson & Johnson has rejected calls to offer patent rights on its HIV medicines to generic drug companies through a" Medicines Patent Pool, created to promote low-cost antiretroviral drugs in low-income countries and the development of new drug combinations and formulations, the Financial Times reports.

4 Jan 2012

CMS assigns J-code for Pharmaxis ARIDOL Bronchial Challenge Test Kit

Pharmaxis, Inc. today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific billing code, or J-code, for ARIDOL (mannitol inhalation powder) Bronchial Challenge Test Kit.

4 Jan 2012

Lundbeck announces availability of ONFI Tablets in the U.S.

Lundbeck announced today that ONFI Tablets are now available for prescribing in the United States. The FDA recently approved ONFI for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.

4 Jan 2012

FDA approves CSL Behring's Berinert for treatment of HAE attacks

CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert, C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder.

4 Jan 2012

Neogen develops new Reveal Q+ test for deoxynivalenol

Neogen Corporation has developed a new test for deoxynivalenol (DON) that combines the speed and simplicity of a lateral flow test with the fully quantitative precision of a more demanding testing method.

4 Jan 2012

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Halaven (eribulin mesylate) Injection.

4 Jan 2012

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Regeneron Pharmaceuticals, Inc. today announced that the Company has entered into a non-exclusive license and partial settlement agreement with Genentech, Inc., a member of the Roche Group relating to U.S. ophthalmic sales of EYLEA (aflibercept) Injection.

3 Jan 2012

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.

3 Jan 2012

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

Cell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI's resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.

3 Jan 2012

Marijuana ingredients appear to affect regional brain function during salience processing

Different ingredients in marijuana appear to affect regions of the brain differently during brain processing functions involving responses to certain visual stimuli and tasks, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Jan 2012

Tamiflu resistant flu on the rise: Study

According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.

2 Jan 2012

Pharmaceutical News

Antiestrogen supplements may reduce risk of melanoma in women with breast cancer

First study to elucidate how statins reduce activation of abnormal blood clotting

Study reveals factors associated with prevention, control of HIV infection

NGP receives investment from Abbott to develop NGP 555 for AD

Arcion receives U.S. patent allowance for ARC-2022 to treat PHN

Actavis commences distribution of Methylphenidate Hydrochloride Extended-Release Capsules

IQWiG examines added benefit of pirfenidone for idiopathic pulmonary fibrosis

MTR technique indicates that COPAXONE therapy results in tissue repair in RRMS patients

Losartan may help prevent smoking-related COPD

J&J will not join Medicines Patent Pool; Company's pharma head says mechanism could 'cause disaster'

CMS assigns J-code for Pharmaxis ARIDOL Bronchial Challenge Test Kit

Lundbeck announces availability of ONFI Tablets in the U.S.

FDA approves CSL Behring's Berinert for treatment of HAE attacks

Neogen develops new Reveal Q+ test for deoxynivalenol

CMS assigns J-code for Eisai's Halaven Injection to treat breast cancer

Regeneron, Genentech enter non-exclusive license and partial settlement agreement for EYLEA

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

Marijuana ingredients appear to affect regional brain function during salience processing

Tamiflu resistant flu on the rise: Study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News